Bumper Offer - Urjas oil Just @ Rs. 1
Maxgalin ER 100 Mg Tablet is a prescription medicine that is available as a Tablet. Neuropathic Pain, Epilepsy, Anxiety are some of its major therapeutic uses. Maxgalin ER 100 Mg Tablet also has some secondary and off-label uses. These are listed below.
The correct dosage of Maxgalin ER 100 Mg Tablet depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Maxgalin ER 100 Mg Tablet as well, which are listed below. Such side effects of Maxgalin ER 100 Mg Tablet normally do not last long and go away once the treatment is completed. Consult your doctor if these side effects become worse or stay for a longer duration.
It is also important to note that Maxgalin ER 100 Mg Tablet has a Moderate effect for pregnant women and Severe effect on lactating mothers. In addition, Maxgalin ER 100 Mg Tablet's effects on the liver, heart and kidney are discussed below in the Maxgalin ER 100 Mg Tablet related warnings section.
Other conditions have been mentioned below in the Maxgalin ER 100 Mg Tablet contraindications section.
Besides this, Maxgalin ER 100 Mg Tablet may also have severe interaction with some medicines. Refer to the list below for further details.
Along with the above-mentioned precautions, remember that taking Maxgalin ER 100 Mg Tablet is considered not safe while driving, and is not addictive.
Maxgalin ER 100 Mg Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Is the use of Maxgalin ER 100 Mg Tablet safe for pregnant women?
Maxgalin can cause unwanted side effects in pregnant women. If you experience any side effects, stop taking Maxgalin right away. Take your doctor's advice before taking it again.
Is the use of Maxgalin ER 100 Mg Tablet safe during breastfeeding?
Women who are breastfeeding may experience severe harmful effects after taking Maxgalin. It should only be taken after medical advice.
What is the effect of Maxgalin ER 100 Mg Tablet on the Kidneys?
Maxgalin rarely affects the kidneys.
What is the effect of Maxgalin ER 100 Mg Tablet on the Liver?
Maxgalin is completely safe for the liver.
What is the effect of Maxgalin ER 100 Mg Tablet on the Heart?
Maxgalin is completely safe for the heart.
Maxgalin ER 100 Mg Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Maxgalin ER 100 Mg Tablet unless your doctor advises you to do so -
Is this Maxgalin ER 100 Mg Tablet habit forming or addictive?
No, you will not get addicted to Maxgalin ER 100 Mg Tablet.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Maxgalin ER 100 Mg Tablet. So it is best to avoid driving.
Is it safe?
Maxgalin ER 100 Mg Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
Maxgalin ER 100 Mg Tablet has been seen to have positive effect on patients with mental disorders.
Interaction between Food and Maxgalin ER 100 Mg Tablet
Taking Maxgalin ER 100 Mg Tablet with food is safe.
Interaction between Alcohol and Maxgalin ER 100 Mg Tablet
Consumption of alcohol and Maxgalin ER 100 Mg Tablet together may have severe effects on your health.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420
